Published:Â January 13th 2025Â |Â Updated:Â February 5th 2025
Teva partners with Klinge Biopharma, Lotus Pharmaceutical for commercialisation of Formycon’s FYB203 (biosimilar aflibercept)
Published:Â January 31st 2024Â |Â Updated:Â May 9th 2024
How biosimilars expand treatment options for patients with retinal disease
Published:Â January 13th 2025Â |Â Updated:Â February 5th 2025
Teva partners with Klinge Biopharma, Lotus Pharmaceutical for commercialisation of Formycon’s FYB203 (biosimilar aflibercept)
Published:Â August 12th 2024Â |Â Updated:Â February 9th 2025
Optimizing diagnosis and surgical management of diabetic retinopathy using advanced imaging technologies
Published:Â November 1st 2023Â |Â Updated:Â February 9th 2025
Spectacle independence for presbyopic patients: Achieving success and satisfaction with ZEISS PRESBYOND, even in a highly demanding cohort
Published:Â April 4th 2024Â |Â Updated:Â February 9th 2025
To Infinity and (PRES)BYOND - The game changer for my practice